Brief: Jyong Biotech Completes Phase II Enrollment Of 700+ Patients For MCS‑8 In Prostate Cancer Prevention Trial
16/09/2025 14:09
Sept 16 (Reuters) - Jyong Biotech Ltd MENS.O: JYONG BIOTECH ANNOUNCES COMPLETION OF PATIENT ENROLLMENT OF OVER 700 SUBJECTS IN PHASE II CLINICAL TRIAL OF MCS‑8 FOR PROSTATE CANCER PREVENTION Source text: ID:nGNX2Qw9Ch Further company coverage: MENS.O ((Reuters.Briefs@thomsonreuters.com;))